Traditional Values
Executive Summary
The rise of the large-volume purchaser of health care scared the industry's strategists into hyperactivity, prompting moves-most prominently by Merck, SmithKline and Lilly-into the service business. These services were designed to take pricing pressure off the companies' core businesses by putting the cost of products into a larger context and helping customers save money in other areas; in the process perhaps also creating another revenue stream for the manufacturer.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.